JeanPaul MD - Inventiva Head Pharmacovigilance
| IVA Stock | USD 2.62 0.04 1.50% |
Insider
JeanPaul MD is Head Pharmacovigilance of Inventiva Sa
| Address | 50 rue de Dijon, Daix, France, 21121 |
| Phone | 33 3 80 44 75 00 |
| Web | https://www.inventivapharma.com |
Inventiva Management Efficiency
The company has Return on Asset of (1.1334) % which means that on every $100 spent on assets, it lost $1.1334. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (16.4276) %, meaning that it generated no profit with money invested by stockholders. Inventiva's management efficiency ratios could be used to measure how well Inventiva manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.62, whereas Return On Tangible Assets are projected to grow to (1.52). At present, Inventiva's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 7.3 M, whereas Non Current Assets Total are forecasted to decline to about 16.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan Kalled | Compass Therapeutics | 61 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Brian MBA | Immunocore Holdings | 57 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Terence Kohler | Verrica Pharmaceuticals | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Jonathan JD | Compass Therapeutics | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| CPA CPA | Vigil Neuroscience | 50 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| MBA MBA | Vaxcyte | 63 | |
| Alessandro MD | Innate Pharma | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Bahija Jallal | Immunocore Holdings | 63 | |
| Byron JD | Janux Therapeutics | 59 | |
| Wayne MD | Janux Therapeutics | 63 | |
Management Performance
| Return On Equity | -16.43 | ||||
| Return On Asset | -1.13 |
Inventiva Sa Leadership Team
Elected by the shareholders, the Inventiva's board of directors comprises two types of representatives: Inventiva inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inventiva. The board's role is to monitor Inventiva's management team and ensure that shareholders' interests are well served. Inventiva's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inventiva's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean Volatier, Chief Officer | ||
| Eric LLM, General Counsel | ||
| Pascaline Clerc, Executive Affairs | ||
| Alice PharmD, Chief Officer | ||
| Frederic Cren, CEO CoFounder | ||
| JeanPaul MD, Head Pharmacovigilance | ||
| Michael Cooreman, Chief Officer | ||
| Pierre Broqua, Chief CoFounder | ||
| Kristina Meyer, Executive Management | ||
| Irena Konstantinova, Head Pharmacology | ||
| Nathalie Harroy, Head Resources |
Inventiva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inventiva a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.43 | ||||
| Return On Asset | -1.13 | ||||
| Operating Margin | (19.11) % | ||||
| Current Valuation | 187.2 M | ||||
| Shares Outstanding | 52.36 M | ||||
| Shares Owned By Institutions | 9.24 % | ||||
| Number Of Shares Shorted | 429.92 K | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 12.35 X | ||||
| Revenue | 17.48 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Inventiva Sa offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inventiva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inventiva Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inventiva Sa Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inventiva Sa. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inventiva. If investors know Inventiva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inventiva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 0.383 | Quarterly Revenue Growth (0.59) | Return On Assets (1.13) | Return On Equity (16.43) |
The market value of Inventiva Sa is measured differently than its book value, which is the value of Inventiva that is recorded on the company's balance sheet. Investors also form their own opinion of Inventiva's value that differs from its market value or its book value, called intrinsic value, which is Inventiva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inventiva's market value can be influenced by many factors that don't directly affect Inventiva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inventiva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inventiva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inventiva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.